Affymetrix

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages) This article needs to be updated. Please help update this article to reflect recent events or newly available information. (March 2020) A major contributor to this article appears to have a close connection with its subject. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. Please discuss further on the talk page. (January 2015) (Learn how and when to remove this message) This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Affymetrix" – news · newspapers · books · scholar · JSTOR (March 2020) (Learn how and when to remove this message) This article has an unclear citation style. The references used may be made clearer with a different or consistent style of citation and footnoting. (March 2020) (Learn how and when to remove this message) (Learn how and when to remove this message)

Affymetrix, Inc.

Company type	Subsidiary
Industry	Biotechnology
Founded	1992
Headquarters	Santa Clara, California, U.S.
Number of locations	11
Key people	Stephen Fodor, Frank Witney (CEO)
Revenue	US$327 Million (FY 2009)[1]
Operating income	US$-30.6 Million (FY 2009)[1]
Net income	US$-23.9 Million (FY 2009)[1]
Total assets	US$612 Million (FY 2009)[2]
Total equity	US$288 Million (FY 2009)[2]
Number of employees	1,141[3]
Parent	Thermo Fisher Scientific
Website	https://www.thermofisher.com/us/en/home/life-science/microarray-analysis.html

Affymetrix is now Applied Biosystems, a brand of DNA microarray products sold by Thermo Fisher Scientific that originated with an American biotechnology research and development and manufacturing company of the same name.^[4] The Santa Clara, California-based Affymetrix, Inc. now a part of Thermo Fisher Scientific was co-founded by Alex Zaffaroni and Stephen Fodor. Stephen Fodor and his group, based on their earlier development of methods to fabricate DNA microarrays using semiconductor manufacturing techniques.^[5][6]

In 1994, the company's first product under the "GeneChip" Affymetrix trademark, an HIV genotyping chip was introduced,^[7] and the company went public in 1996.^[8]

After incorporation, Affymetrix grew in part by acquiring technologies from other companies, including Genetic MicroSystems (slide-based Microarrays and scanners)^{[citation needed]} and Neomorphic (for bioinformatics) in 2000,^[9] ParAllele Bioscience (custom SNP genotyping),^{[citation needed]} USB/Anatrace (biochemical reagents) in 2008,^[10] Panomics (low to mid-plex applications) in 2008,^{[citation needed]} and eBioscience (flow cytometry) in 2012.^[11] Affymetrix spun off Perlegen Sciences in 2000,^[12][13] as a discrete business focusing on wafer-scale genomics to characterize population-variance of genomic markers.^[14]

In January 2014, the Food and Drug Administration approved Affymetrix's postnatal blood test, CytoScan Dx Assay, looking at whole-genome correlates of congenital abnormalities and other causes of childhood developmental delay.^[15]

On January 8, 2016, Thermo Fisher Scientific announced its acquisition of Affymetrix for approximately $1.3 billion,^[16] which closed on March 31, 2016.^[17]

Affymetrix, Inc. was spun-off from Affymax Research Institute by Alex Zaffaroni in 1993, and was eventually based in Santa Clara, California, United States.^[18] It began as a unit in Affymax N.V. in 1991 under Fodor and his group.^[18][19] In the late 1980s, that group had developed methods for fabricating DNA microarrays, under the "GeneChip" Affymetrix trademark, using semiconductor manufacturing techniques.^{[citation needed]} The company's first product, an HIV genotyping GeneChip, was introduced in 1994^{[citation needed]} and the company went public in 1996.^[20]

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages) This section does not cite any sources. Please help improve this section by adding citations to reliable sources. Unsourced material may be challenged and removed. (March 2020) (Learn how and when to remove this message) This article needs to be updated. Please help update this article to reflect recent events or newly available information. (March 2020) (Learn how and when to remove this message)

Affymetrix, Inc. made glass chips for analysis of DNA Microarrays called GeneChip arrays, and sold mass-produced GeneChip arrays intended to match scientifically important parts of human and other animal genomes. Manufactured using photolithography, Affymetrix's GeneChip arrays assisted researchers in quickly scanning for the presence of particular genes in a biological sample. In this area, Affymetrix was focused on oligonucleotide microarrays, which could be used to address the presence of genes through detection of specific corresponding segments of mRNA. The single-use chips could be used to analyze thousands of genes in a single assay. The company also manufactured machinery for high speed analysis of biological samples, and its GeneChip Operating Software as a system for managing Affymetrix microarray data.

Affymetix's competitors in the DNA Microarray business include Illumina, GE Healthcare, Applied Biosystems, Beckman Coulter, Eppendorf Biochip Systems, and Agilent.

Prior to its acquisition by Thermo Fisher, and its becoming a line of its products, Affymetrix, Inc. had acquired the technologies of a number of companies. It acquired Genetic MicroSystems for slide-based microarrays and scanners and Neomorphic for bioinformatics, both in 2000,^[21][22] ParAllele Bioscience for custom SNP genotyping,^{[when?][citation needed]} USB/Anatrace for biochemical reagents in 2008,^{[verification needed][23]} eBioscience for flow cytometry in 2012,^{[verification needed][24]} and Panomics in 2008^{[verification needed][25]} and True Materials^[when?] to expand its offering of low to mid-plex applications.^[26][27] In 2000, Perlegen Sciences spun out from Affymetrix to focus on wafer-scale genomics for massive data creation and collection required for characterizing population variance of genomic markers and expression for the drug discovery process.^{[citation needed]}

In January 2014, the Food and Drug Administration cleared a first-of-a-kind whole-genome postnatal blood test that can aid physicians in identifying the underlying genetic cause of developmental delay, intellectual disability, congenital anomalies, or dysmorphic features in children, where it was noted that "[a]bout 2 to 3 percent of U.S. children have some sort of intellectual disability, according to the National Institutes of Health."^[28] The test, known as CytoScan Dx Assay, was designed to diagnose these disabilities earlier to expedite appropriate care and support.

• "Affymetrix—Corporate History". Affymetrix. Archived from the original on 2006-11-07. Retrieved 2006-11-20. Detailed, multi-document resource on the originating company's history, from its perspective, featuring a detailed timeline of acquisitions, photographs of early technology, etc.